Wild-type (senile) amyloidosis other diagnostic studies

Wild-type (senile) amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) amyloidosis other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) amyloidosis other diagnostic studies
CDC on Wild-type (senile) amyloidosis other diagnostic studies
Wild-type (senile) amyloidosis other diagnostic studies in the news
Blogs on Wild-type (senile) amyloidosis other diagnostic studies
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Other Diagnostic Studies

Other diagnostic studies that help in diagnosing wild type amyloidosis include cardiac biomarkers, histopathological diagnosis and genetic testing.

Other Diagnostic Studies
Cardiac biomarkers	Brain natriuretic peptide (BNP), N-terminal fragment of BNP (NT-proBNP) and cardiac troponins. Elevation of NT-proBNP indicates the presence of left ventricular abnormalities in patients with familial mutation in ATTR Used as a screening test to initiate workup for ATTRm-CA Increasing serum levels of BNP, NT-proBNP and troponins were shown to have a progressive correlation with disease severity and worse outcomes Monitoring of these cardiac biomarkers is being employed to monitor treatment
Histopathological diagnosis	EMB with histopathology remains the gold standard for diagnosis of cardiac amyloidosis. Histopathology demonstrates deposition of amorphous deposits of amyloid fibrils in the heart. The binding of Congo red stain to the deposited amyloid fibrils leads to characteristic apple-green birefringence under polarized light microscopy and an intense yellow-green fluorescence is seen when binding to thioflavin. Precursor protein identification can be accomplished by immunohistochemistry, electron microscopy, or mass spectrometry (preferred), depending upon institutional expertise. Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma. EMB is associated with risks of complications such as Ventricular free-wall perforation Arrhythmia Conduction abnormalities
Genetic testing	DNA sequencing for the transthyretin gene Absence of amino acid sequence abnormalities by mass spectrometry is consistent with ATTRwt-CA Presence of a pathologic mutation Predict sites of organ involvement Family history